Literature DB >> 31749512

Non-inferiority Testing for Risk Ratio, Odds Ratio and Number Needed to Treat in Three-arm Trial.

Shrabanti Chowdhury1, Ram C Tiwari2, Samiran Ghosh3,1.   

Abstract

Three-arm non-inferiority (NI) trial including the experimental treatment, an active reference treatment, and a placebo where the outcome of interest is binary are considered. While the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness), however, recent FDA guideline suggested measures such as relative risk (RR), odds ratio (OR), number needed to treat (NNT) among others, on the basis of which NI can be claimed for binary outcome. Albeit, developing test based on these different functions of binary outcome are challenging. This is because the construction and interpretation of NI margin for such functions are non-trivial extensions of RD based approach. A Frequentist test based on traditional fraction margin approach for RR, OR and NNT are proposed first. Furthermore a conditional testing approach is developed by incorporating assay sensitivity (AS) condition directly into NI testing. A detailed discussion of sample size/power calculation are also put forward which could be readily used while designing such trials in practice. A clinical trial data is reanalyzed to demonstrate the presented approach.

Entities:  

Keywords:  Assay Sensitivity; Binary Outcome; Fraction Margin; Non-inferiority Margin; Odds/Risk Ratio/NNT; Three-arm Trial

Year:  2018        PMID: 31749512      PMCID: PMC6867690          DOI: 10.1016/j.csda.2018.08.018

Source DB:  PubMed          Journal:  Comput Stat Data Anal        ISSN: 0167-9473            Impact factor:   1.681


  25 in total

1.  A simple procedure to compute the sample size needed to compare two independent groups when the population variances are unequal.

Authors:  J Singer
Journal:  Stat Med       Date:  2001-04-15       Impact factor: 2.373

2.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.

Authors:  Iris Pigeot; Juliane Schäfer; Joachim Röhmel; Dieter Hauschke
Journal:  Stat Med       Date:  2003-03-30       Impact factor: 2.373

3.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

4.  On the three-arm non-inferiority trial including a placebo with a prespecified margin.

Authors:  Eisuke Hida; Toshiro Tango
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

5.  Planning and analysis of three-arm non-inferiority trials with binary endpoints.

Authors:  Meinhard Kieser; Tim Friede
Journal:  Stat Med       Date:  2007-01-30       Impact factor: 2.373

6.  Statistical methods for the analysis of two-arm non-inferiority trials with binary outcomes.

Authors:  Stefan Wellek
Journal:  Biom J       Date:  2005-02       Impact factor: 2.207

7.  A mixed approach for proving non-inferiority in clinical trials with binary endpoints.

Authors:  Valentin Rousson; Burkhardt Seifert
Journal:  Biom J       Date:  2008-04       Impact factor: 2.207

8.  Noninferiority trial designs for odds ratios and risk differences.

Authors:  Joan F Hilton
Journal:  Stat Med       Date:  2010-02-26       Impact factor: 2.373

9.  The number needed to treat: a clinically useful measure of treatment effect.

Authors:  R J Cook; D L Sackett
Journal:  BMJ       Date:  1995-02-18

10.  Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints.

Authors:  Nian-Sheng Tang; Bin Yu; Man-Lai Tang
Journal:  BMC Med Res Methodol       Date:  2014-12-18       Impact factor: 4.615

View more
  1 in total

1.  New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.

Authors:  Samiran Ghosh; Erina Paul; Shrabanti Chowdhury; Ram C Tiwari
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.